Yes, for some patients with knee osteoarthritis, gel injections can reduce pain and improve function for months at a time. The effect is real but modest, it varies widely between people, and it does not rebuild cartilage or change the course of the disease. Whether a gel injection "works" depends on which gel, which patient, and what outcome you are measuring.
The gels in question are called viscosupplements. They are injections of hyaluronic acid, a molecule that normally gives synovial fluid its slippery, shock-absorbing quality. In osteoarthritic knees, that fluid becomes thinner and less protective. The idea behind the injection is to restore some of that cushioning and lubrication. The evidence supports a smaller and more conditional benefit than the marketing suggests, and the details matter more than the headline.
How hyaluronic acid changes an arthritic knee
Healthy synovial fluid is a dialysate of blood plasma thickened by hyaluronic acid, a long-chain polysaccharide. One hyaluronic acid molecule can hold many times its weight in water, which is why the fluid behaves like a viscous lubricant rather than like water. It coats the cartilage surface, reduces friction between opposing surfaces, and helps distribute load across the joint. It also binds to receptors on cartilage cells and synovial cells, which can dampen inflammatory signaling.
In osteoarthritis, the concentration and molecular weight of hyaluronic acid in the joint fall. The fluid becomes less viscous and less able to cushion impact. The cartilage loses proteoglycans, the joint lining becomes inflamed, and the mechanical environment degrades. An injection of exogenous hyaluronic acid temporarily raises the viscosity of the fluid and may also exert anti-inflammatory effects on the synovium.
The mechanism is mostly mechanical and partly biological. The mechanical part is straightforward: thicker fluid lubricates better and absorbs some shear. The biological part is less certain. Laboratory studies suggest hyaluronic acid can reduce inflammatory mediators and protect cartilage cells, but whether that translates into meaningful clinical benefit in people is not established. The injected molecule is cleared from the joint over days to weeks, yet pain relief often outlasts its detectable presence. That mismatch suggests the benefit is not purely from lubrication. A plain-language version: the gel may help the joint feel better partly by changing the chemical conversation inside the knee, not just by greasing it.
What the trials actually measure
The clinical evidence comes mostly from randomized controlled trials comparing hyaluronic acid injections with saline injections or with no injection. The outcomes measured are pain scores, function scores, and patient global assessment. The results are consistent in direction but modest in size.
Across trials, hyaluronic acid injections typically produce a pain improvement of roughly 0.3 to 0.5 standard deviations compared with saline, which corresponds to a small-to-moderate effect. The number needed to treat for a clinically meaningful improvement is generally in the range of 4 to 8 patients, depending on the preparation and the population. Effects appear within two to four weeks and generally peak around eight to twelve weeks. Many trials report benefit persisting to six months, though the confidence intervals widen over time.
The placebo response in these trials is large. Saline injections themselves reduce pain substantially, which means any trial without a sham comparator overstates the specific effect of the gel. The best-designed trials use a blinded saline control, and in those trials the advantage of hyaluronic acid shrinks. This is the counterintuitive detail that professional reviews emphasize: much of the perceived benefit of a gel injection may come from the injection itself, the expectation, and the natural fluctuation of osteoarthritis symptoms.
Different preparations are not interchangeable. Higher molecular weight and cross-linked formulations are designed to stay in the joint longer, and some trials suggest they produce larger or more durable effects than lower molecular weight products. The evidence is not strong enough to rank preparations confidently, and the differences between them are modest at best.
Comparing gel injections with other options
| Option | What it is | Typical duration of benefit | Key limitation |
|---|---|---|---|
| Hyaluronic acid injection | Gel injected into the joint, often in a series | Weeks to about six months | Modest effect; placebo response large |
| Corticosteroid injection | Steroid injected into the joint | Days to a few weeks, sometimes longer | Repeated use can accelerate cartilage loss |
| Oral NSAIDs | Anti-inflammatory pills | While taken | GI, cardiovascular, and kidney risks |
| Physical therapy | Exercise and strengthening program | Ongoing if maintained | Requires adherence and time |
| Weight loss | Reduced joint load | Ongoing | Requires sustained behavioral change |
| Total knee replacement | Surgery | Years | Major surgery, recovery, revision risk |
The table makes the trade-offs clear in a way prose cannot. Steroids act fast but fade fast. NSAIDs work while you take them but carry systemic risk. Physical therapy and weight loss are slow and require effort but have no injection-related risk. Surgery is definitive but irreversible. Hyaluronic acid sits in the middle: more durable than a steroid, less durable than surgery, and safer than chronic NSAID use for many patients.
Who benefits and who does not
The patients most likely to benefit are those with mild to moderate osteoarthritis, preserved joint space, and pain that is mechanical rather than inflammatory. Younger patients and those with higher baseline function tend to respond better. Patients with severe disease, bone-on-bone changes, or significant malalignment are less likely to benefit, because the problem is structural rather than lubricative.
Response is also idiosyncratic. Some patients report dramatic relief from a single series; others report none. Because there is no reliable way to predict who will respond, a trial of therapy is often the only way to know. If the first series produces no meaningful benefit, repeating it is unlikely to help.
Red-flag warnings to discuss with a clinician before any injection:
Signs of joint infection: fever, severe swelling, warmth, or redness around the knee Known allergy to hyaluronic acid preparations or their components Anticoagulation or bleeding disorders, given the small risk of bleeding into the joint Recent intra-articular steroid injection, which some clinicians space apart from gel injections Skin infection or rash over the injection site Prosthetic knee joint, since these products are not intended for use in prosthetic joints
These warnings are not a reason to avoid evaluation. They are a reason to have the conversation with a clinician who knows your history. This article cannot make that judgment for you.
Practical steps and thresholds
The practical question is not whether gel injections work in general but whether they are worth trying for a specific knee. A reasonable sequence is to confirm the diagnosis, address modifiable load factors, and then consider injections as one option among several.
Concrete steps:
Confirm the diagnosis with imaging and a clinical exam, since not all knee pain is osteoarthritis. Address load first: even modest weight loss reduces knee load, and strengthening the quadriceps improves function. Try a conservative program for at least six to eight weeks before injections, unless pain is severe. If injections are chosen, expect a series rather than a single shot, since most regimens involve three to five injections spaced about a week apart. Judge the result at eight to twelve weeks, not at one week, because the effect builds. If there is no meaningful improvement after a full series, do not repeat it without reassessing the diagnosis.
The thresholds used in trials are worth knowing. A clinically meaningful pain improvement is often defined as a reduction of about 20 percent or more on a validated scale, or roughly a one-point change on a ten-point scale. Function improvements are judged similarly. A patient who feels no better than before the series has not crossed that threshold and should reconsider the approach.
Limits of the evidence and honest caveats
The evidence has real limitations. Trials vary in preparation, dose, number of injections, and patient selection, which makes pooling difficult. Blinding is imperfect because the gel is visibly different from saline, so some trials cannot fully separate specific from nonspecific effects. Follow-up beyond one year is limited, so claims about long-term disease modification are unsupported.
Guideline bodies differ in their recommendations. Some major musculoskeletal societies conditionally recommend hyaluronic acid for knee osteoarthritis, while others recommend against it or recommend it only for selected patients. The disagreement reflects the modest effect size, the cost, and the large placebo response. The honest summary is that the treatment is safe for most patients, provides modest short-term benefit for some, and does not alter the underlying disease.
There is also a cost dimension. Prices vary widely by country and setting, so this article does not state figures that would be outdated or misleading. Patients should ask about total cost, including the series and any imaging or visit fees, before committing.
This article is explanatory and is not a substitute for individualized medical advice. Decisions about injections belong with a clinician who can examine the knee, review the history, and weigh the alternatives. The evidence supports a conditional yes, not a universal one.